Physician profile
Thomas K Obrien
NPI 1952322588
$14,644.39
in general payments reported to CMS, 2019-2025
40 companies · $563 in 2025
The $563 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,394 · 2020: $2,084 · 2021: $3,024 · 2022: $2,667 · 2023: $2,251 · 2024: $1,662 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,475.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,887.38 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,175.37 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $1,137.24 | 2019-2024 | |
| Novo Nordisk INC | $985.76 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $850.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $708.02 | 2019-2022 | |
| Amgen INC. | $661.43 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $594.07 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $560.99 | 2019-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $475.82 | 2019-2023 | Eliquis |
| Astellas Pharma US INC | $433.40 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $245.53 | 2022-2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $229.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $210.06 | 2019-2022 | |
| Amarin Pharma, INC. | $191.49 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.